Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis

G Visco, L Alba, S Grisetti, P Guarascio, P Narciso, P Sette, C Struglia, G Tossini, V Tozzi

Abstract
Results are reported for a small study of 11 patients positive for HIV and with chronic active viral hepatitis. Low dose zidovudine/interferon alfa-2b combined treatment produced a general reduction in alanine aminotransferase activities and increased the CD4 lymphocyte count, hepatitis B e antigen, and the loss of HIV p24 antigen. The treatment was well tolerated and progression of HIV disease was not seen.

(Gut 1993; supplement: S107-S108)

A study was done to evaluate the efficacy and toxicity of zidovudine plus interferon alfa-2b in the treatment of patients with HIV infection and chronic active hepatitis proved by liver biopsy examination because of hepatitis B virus (HBV), hepatitis delta virus (HDV), hepatitis C virus (HCV) infection, or a combination of these.

Patients and methods
For inclusion in the study, patients were required to have raised serum transaminase activities, (between 2.5 and 8 times the upper limit of normal for at least six months). Serological signs of viral replication were to be present both in HBV and in HCV (not in HDV) patients. Therefore, they had to be: (a) positive for anti-HCV antibody (ELISA) plus viral HCV-RNA (polymerase chain reaction (PCR)) in C hepatitidis; (b) positive for hepatitis B surface antigen (HBsAg) plus HBV-DNA or hepatitis B e antigen (HBeAg) in B hepatitidis; (c) positive for HBsAg plus anti-HDV antibody in HDV. Chronic active hepatitis proved by liver histology was required to be present not more than six months before treatment. Anti-HIV antibody positivity was shown, using ELISA and western blot, and CD4+ lymphocyte counts were to be lower than 500/mm3. All patients gave their informed consent to take part in this study.

A total of 11 anti-HIV-positive patients (nine men and two women, aged 27-33) were enrolled in the trial. Risk factors for infection consisted of heroin addiction in nine patients, homosexual contacts in one, and heterosexual contacts in one. HIV disease stage (Centers for Disease Control) classification was IV C2 in eight patients, IV C1 in one, and II in two patients. Testing for hepatitis viral markers showed anti-HCV alone in five patients, replicating both HCV and HBV in two, non-replicating HBV plus anti-HDV in two, and replicating both HCV and HBV plus anti-HDV in two. Three patients of 11 were positive for HIV p24 antigen (HIV p24 Ag).

The five patients with HCV-related chronic active hepatitis received oral zidovudine 250 mg at 12 hour intervals (500 mg/day) plus interferon alfa-2b 3 million units (MU) three times weekly by subcutaneous injection. The remaining six (two with HBV/HDV related disease, two with HBV/HCV related disease, and two with HCV/HDV related disease) each received zidovudine 500 mg/day plus interferon alfa-2b 5 MU three times weekly. All patients were followed up for three to 12 months.

Serum alanine aminotransferase activities (ALT), white blood cell, and platelet counts were measured every month, while HBeAg, CD4 lymphocytes, and HIV p24 Ag were measured every third month. The clinical progression of HIV infection was assessed using the Centers for Disease Control staging system.

Results
After two months of treatment, four of 11 patients (36-4%) had normalised serum ALT activities and by the sixth month five patients (45-5%) had normal values (Fig 1). Mean ALT activities fell from >258 IU/l (n=11) to 133 IU/l (n=8) during six months of treatment with zidovudine and interferon, with significant

---

**Figure 1** Normalisation of serum ALT activities.
differences at three and six months compared with baseline values (Fig 2). After two months of treatment, ALT activities became normal in four of five HCV patients, one of two HBV+HCV patients (and remained normal after six months), and in one of two HBV+HCV+HDV patients. In contrast, ALT activities were almost unchanged in the two patients with disease unrelated to HCV (non-replicating HBV/HDV-related chronic active hepatitis patients).

Mean levels of CD4 lymphocytes fluctuated during treatment with zidovudine and interferon but showed an overall tendency to increase (Fig 3). The Table shows changes in HBeAg and HIV p24 Ag positivity in patients continuing on treatment for up to 12 months. Three of six HBeAg positive patients seroconverted to anti-HBe, and all three HIV p24 Ag positive patients became negative within three months of treatment.) Flu like symptoms were seen in three (43%) of seven patients treated with zidovudine 500 mg/day plus the higher dose (5 MU three times weekly) of interferon alfa-2b. No progression of HIV related disease was seen.

**Conclusions**

The results of this small study in HIV positive patients with viral hepatitis suggest that combined treatment with low dose zidovudine (500 mg/day) and interferon alfa-2b (3 or 5 MU three times weekly) can reduce serum ALT activities, increase CD4 lymphocytes count, and promote HBe seroconversion, mostly in patients with HBV or HCV replicating infections or both. It also favours the loss of HIV p24 Ag.

**TABLE** Changes in HBeAg and HIV p24 Ag positivity in treated patients

<table>
<thead>
<tr>
<th>Treatment (month)</th>
<th>0</th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n)</td>
<td>11</td>
<td>11</td>
<td>8</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>HBeAg positive (n)</td>
<td>6/6</td>
<td>6/6</td>
<td>4/6</td>
<td>2/4</td>
<td>1/2</td>
</tr>
<tr>
<td>HIV p24 Ag positive (n)</td>
<td>3/11</td>
<td>0/8</td>
<td>0/8</td>
<td>0/5</td>
<td>0/3</td>
</tr>
</tbody>
</table>
Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis.

G Visco, L Alba, S Grisetti, P Guarascio, P Narciso, P Sette, C Struglia, G Tossini and V Tozzi

Gut 1993 34: S107-S108
doi: 10.1136/gut.34.2_Suppl.S107

Updated information and services can be found at:
http://gut.bmj.com/content/34/2_Suppl/S107

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/